CompletedPhase 2

Rituximab for the Treatment of Severe Ocular Manifestations of Behcet's Disease

Iran20 participantsStarted 2006-04

Plain-language summary

The purpose of this study is to find if Rituximab can improve severe ocular lesions of Behcet's Disease.

Who can participate

Age range16 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Behcet's Disease fulfilling the new International Criteria for Behcet's Disease * Having active ocular lesions (posterior and/or retinal vasculitis) * Resistant to cytotoxic drugs + prednisolone 0.5 mg/kg Exclusion Criteria: * Visual acuity less than 1/10 on Snellen chart * Antecedent of allergic reaction to any component of the therapeutic regimen

What they're measuring

Visual acuity

Timeframe: 6 months

Trial details

NCT IDNCT00664599

SponsorTehran University of Medical Sciences

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2008-01

View on ClinicalTrials.gov More Behcet's Syndrome trials